News
-
-
-
COMMUNIQUÉ DE PRESSE
Meril Life Sciences Presents One-year Outcomes from the LANDMARK Randomized Controlled Trial at PCR London Valves 2025
Meril Life Sciences presents one-year outcomes from the LANDMARK Randomized Controlled Trial at PCR London Valves 2025, comparing THV series in aortic stenosis patients. Study highlights Myval THV series performance in clinical efficacy and patient safety